Treating Hormone-Receptor–Positive Breast Cancer
Despite improvements resulting from the use of adjuvant endocrine therapy and aromatase inhibitors in luminal breast cancer, the risk of recurrence continues indefinitely, with more than half diagnosed after the first 5 years. Extended therapy appears reasonable, but the most effective duration is unknown. New research findings are summarized in a short video.
Copyright © 2021 Massachusetts Medical Society.
